ID: ALA5183549

Max Phase: Preclinical

Molecular Formula: C21H16ClFN4O

Molecular Weight: 394.84

Associated Items:

Representations

Canonical SMILES:  Cc1nn(-c2cccc(Cl)c2F)c(C)c1C(=O)Nc1ccc2ccccc2n1

Standard InChI:  InChI=1S/C21H16ClFN4O/c1-12-19(13(2)27(26-12)17-9-5-7-15(22)20(17)23)21(28)25-18-11-10-14-6-3-4-8-16(14)24-18/h3-11H,1-2H3,(H,24,25,28)

Standard InChI Key:  RWSLCRRNRLCYRD-UHFFFAOYSA-N

Associated Targets(Human)

Protein Wnt-3a 90 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 394.84Molecular Weight (Monoisotopic): 394.0997AlogP: 5.08#Rotatable Bonds: 3
Polar Surface Area: 59.81Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 2.34CX LogP: 4.98CX LogD: 4.98
Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.53Np Likeness Score: -1.98

References

1. Ai Y, Sakamuru S, Imler G, Xia M, Xue F..  (2022)  Improving the solubility and antileukemia activity of Wnt/β-catenin signaling inhibitors by disrupting molecular planarity.,  69  [PMID:35777269] [10.1016/j.bmc.2022.116890]

Source